Literature DB >> 24464671

Colon carcinoma treated with oxaliplatin and capecitabine in a 12-year-old child.

Dong-Lai Hu1, Xiao-Dong Guo, Zhi-Nan Sun, Yan-Min Zhao.   

Abstract

BACKGROUND: XELOX (oxaliplatin 130 mg/m(2) iv, capecitabine 1000 mg/m(2) bid oral d1-14, q3w) chemotherapy has never been used in children. In this report, we present a case of a 12-year-old girl with colon adenocarcinoma, treated with surgery and XELOX chemotherapy.
METHODS: On admission, the girl complained of abdominal pain and intestinal obstruction. Physical examination revealed a distended abdomen with tenderness on the left upper quadrant. Barium enema revealed a stenotic lesion at the distal end of the transverse colon, and abdominal computed tomography showed acute obstruction and a colonic mass. Laparotomy was performed after the failure of conservative treatment.
RESULTS: The mass was originated from the transverse colon. Frozen sections of the specimens revealed an adenocarcinoma. Transverse colectomy was performed and regional lymph nodes were removed. Pathological examination confirmed that the mass was a poorly differentiated adenocarcinoma, and XELOX chemotherapy was used. No evidence of recurrent or metastatic tumor was found after 18 months.
CONCLUSION: Although complete resection is the most effective treatment, XELOX chemotherapy is beneficial to the improvement of clinical outcome of patients with colon adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464671     DOI: 10.1007/s12519-014-0459-z

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  15 in total

1.  Adenocarcinoma of the colon in a 9-month-old infant; report of a case.

Authors:  W H KERN; W C WHITE
Journal:  Cancer       Date:  1958 Jul-Aug       Impact factor: 6.860

2.  Colorectal carcinoma in children.

Authors:  R A Brown; H Rode; A J Millar; C Sinclair-Smith; S Cywes
Journal:  J Pediatr Surg       Date:  1992-07       Impact factor: 2.545

3.  Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

Authors:  Hans-Joachim Schmoll; Thomas Cartwright; Josep Tabernero; Marek P Nowacki; Arie Figer; Jean Maroun; Timothy Price; Robert Lim; Eric Van Cutsem; Young-Suk Park; Joseph McKendrick; Claire Topham; Gemma Soler-Gonzalez; Filipo de Braud; Mark Hill; Florin Sirzén; Daniel G Haller
Journal:  J Clin Oncol       Date:  2007-01-01       Impact factor: 44.544

4.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Authors:  Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

Review 5.  Epidemiology and management options for colorectal cancer in children.

Authors:  Raya Saab; Wayne L Furman
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Adenocarcinoma of the colon in children presenting as abdominal pain: report of two cases.

Authors:  Hsiang-Hung Shih; Chung-Ching Lu; Mao-Meng Tiao; Sheung-Fat Ko; Jiin-Haur Chuang
Journal:  Chang Gung Med J       Date:  2002-05

7.  Childhood, adolescents, and young adults (≤25 y) colorectal cancer: study of Anatolian Society of Medical Oncology.

Authors:  Muhammet A Kaplan; Abdurrahman Isikdogan; Mahmut Gumus; Ulku Y Arslan; Caglayan Geredeli; Nuriye Ozdemir; Dogan Koca; Faysal Dane; Ali Suner; Emin T Elkiran; Mehmet Kucukoner; Mesut Seker; Kaan Helvaci; Tunc Guler; Dogan Uncu; Ali Inal; Ramazan Yildiz
Journal:  J Pediatr Hematol Oncol       Date:  2013-03       Impact factor: 1.289

8.  Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma.

Authors:  M P LaQuaglia; G Heller; D A Filippa; A Karasakalides; V Vlamis; N Wollner; W E Enker; A M Cohen; P R Exelby
Journal:  J Pediatr Surg       Date:  1992-08       Impact factor: 2.545

9.  Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Authors:  Hendrik-Tobias Arkenau; Dirk Arnold; Jim Cassidy; Eduardo Diaz-Rubio; Jean-Yves Douillard; Howard Hochster; Andrea Martoni; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll; Rainer Porschen
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

10.  Clinical management of localized colon cancer with capecitabine.

Authors:  J Quidde; D Arnold; A Stein
Journal:  Clin Med Insights Oncol       Date:  2012-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.